The Neuroendocrine Tumors market is witnessing robust industry growth driven by advancements in targeted therapies and increasing diagnostic capabilities. The market’s evolution is shaped by breakthroughs in immunotherapy and personalized medicine, making it a dynamic sector with substantial business growth opportunities from 2026 onward.

Market Size and Overview

The Global Neuroendocrine Tumors Market is estimated to be valued at USD 5.11 billion in 2025 and is expected to reach USD 7.89 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

This growth trajectory is supported by the rising prevalence of neuroendocrine tumors, favorable regulatory approvals, and enhanced research activities spotlighting Neuroendocrine Tumors Market Opportunities. Market trends indicate intensified focus on early diagnosis and novel therapeutic development, which contribute strongly to the overall market scope and revenue generation.

Core Market Segments
The Neuroendocrine Tumors market segments include Product Type, End User, and Application.
- Product Type: This comprises targeted therapies, immunotherapy, and diagnostic agents. Targeted therapies dominate, capturing substantial market revenue, while immunotherapy is the fastest-growing segment, with a growth rate exceeding 10% in 2024 due to new clinical pipeline assets. A notable example is the 2025 clinical expansion of a novel antibody-drug conjugate launched by ADC Therapeutics, driving immunotherapy adoption.
- End User: Hospitals, specialty clinics, and diagnostic centers comprise this segment. Hospitals remain the dominant end user by patient volume. However, specialty clinics exhibit faster growth, fueled by outpatient treatment preferences and better accessibility. Seneca Therapeutics expanded its distribution network in specialty clinics in 2024, capitalizing on this trend.
- Application: Divided into lung, gastrointestinal, pancreas, and others. Gastrointestinal neuroendocrine tumors lead in incidence and market revenue, while pancreatic NETs show accelerated revenue growth reflecting heightened R&D focus on that application, supported by successful approvals in recent years.

‣ Get more insights on: Neuroendocrine Tumors Market

‣ Get this Report in Japanese Language: 神経内分泌腫瘍市場

‣ Get this Report in Korean Language: 신경내분비종양시장

‣ Read More Related Articles: Prevalence of Ulcerative Colitis Continues to Rise in the UK